AMP applauds Supreme Court ruling: Sees win for patients and personalized medicine

March 21st, 2012
Bethesda, MD, March 21, 2012: "The Association for Molecular Pathology (AMP) applauds the U.S. Supreme Court's ruling today in the case of Mayo Collaborative Services v. Prometheus Laboratories as a victory for patients and for the advancement of personalized medicine," stated Iris Schrijver, MD, the Organization's President. AMP, an international professional society representing more than 2000 physicians, doctoral scientists, and medical technologists, joined 10 other medical and healthcare organizations in filing an amicus brief with the Court in support of Mayo Clinic. AMP is also the lead plaintiff in Association for Molecular Pathology v. U.S. Patent and Trademark Office that challenges the validity of patents on two human genes associated with hereditary breast and ovarian cancer and is currently under review by the High Court.

"Prometheus acknowledged that physicians can infringe the patent by merely thinking about the relationship between drug metabolite levels and patient response," asserted Dr. Schrijver. "It is encouraging that the Court recognized that the Prometheus patents neither promote the advancement of medical practice, nor benefit patient care".

"In Prometheus, the Court wisely recognized that overly broad patents can inhibit innovation," stated Jennifer Hunt, MD, MEd, the Organization's President-Elect. "Establishing a drug reference range is important, but standard work for laboratory physicians. Awarding monopolies over the medical use of natural, biological relationships stifles innovation in true diagnostic test methods and obstructs improvements for patient care."

AMP believes the Supreme Court's reasoning in Mayo v. Prometheus extends to patents that claim ownership over another type of natural phenomenon, the biological relationships between genetic variants and clinical disease. Such relationships are at the heart of personalized medicine. "Patients are increasingly being disadvantaged by gene correlation patents," stated Roger D. Klein, MD, JD, Chair of AMP's Professional Relations Committee. As an example, Dr. Klein cited a method patent relating to a variation in a gene known as FLT3 that is used to qualify some leukemia patients for bone marrow transplant.

Enforcement of the FLT3 patent by a private company has been forcing physicians and laboratories to split and geographically distribute irreplaceable bone marrow specimens. "Splitting samples creates an additional risk of specimen loss and delays the receipt of patient results" stated Dr. Klein. "In addition, it interferes with the ability of pathologists to provide synoptic interpretations involving multiple tests, and prevents them from implementing cost saving algorithms that limit unnecessary testing. The Supreme Court's ruling is clearly a win both for our patients and for personalized healthcare."

Provided by Association for Molecular Pathology

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

A nanosized hydrogen generator

(Phys.org) —Researchers at the US Department of Energy's (DOE) Argonne National Laboratory have created a small scale "hydrogen generator" that uses light and a two-dimensional graphene platform to boost ...

The curious case of the fluctuating speed of light

Suppose you were an electrician. You've trained, apprenticed, passed all your certifications, and you've worked with electric wiring for years. You've wired houses and commercial buildings for years, and ...